Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JASPIS-01 of MEN1703 alone and with glofitamab in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
2024-513098-31-00Phase 2Authorised
- Sponsor
- Ryvu Therapeutics
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of dapolsertib, glofitamab and obinutuzumab in mature B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Ryvu Therapeutics. Primary endpoints: Incidence and severity of adverse events, Complete response rate and 1 more. Planned start Nov 2024; status: authorised.
02
Drugs
dapolsertibglofitamabobinutuzumab
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2024-513098-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513098-31-00.